$BMY news
The latest BMY stock news: headlines, filings, AI summaries and sentiment for $BMY, updated around the clock.
- Bristol Myers Squibb to Unify Research and Development Organization in 2025
- Bristol Myers Squibb Reports Positive Long-Term Phase 3 Data for Camzyos in Pediatric Patients
- Halozyme Reports Strong Q3 2026 Results with Significant Revenue Growth and Raised Guidance
- BioNTech Reports Q3 2026 Earnings with Profit Turnaround and Oncology Progress
- Bristol Myers Squibb Q3 Revenue Grows 7% Driven by Expanding Growth Drug Portfolio
- Bristol-Myers Squibb Reports Q3 2026 Revenue Growth Driven by Growth Portfolio
- Bristol Myers Squibb Raises Full-Year Guidance Amid Growth Portfolio Strength
- BRISTOL MYERS SQUIBB CO - 10-Q Filing
- Bristol-Myers Squibb Reports Q3 Earnings Beat and Raises 2026 Revenue Guidance
- Bristol Myers Squibb Reports 1% Increase in Legacy Revenue and 12% Growth in New Portfolio Sales
- BRISTOL MYERS SQUIBB CO - 8-K Filing
- Bristol-Myers Squibb Scheduled to Report Q3 2026 Earnings
- Bristol Myers Squibb Reports Positive Phase 3 Trial Results for Lung Cancer Drug Iza-bren
- ESMO Congress Highlights Oncology Breakthroughs Amid Market Volatility and Fed Uncertainty
- Bristol Myers Squibb and Novo Nordisk Comparative Revenue Analysis
- Revenue Comparison: Eli Lilly's GLP-1 Growth vs. Bristol Myers Squibb's Steady Performance
- Comparative Revenue Analysis of AbbVie and Bristol Myers Squibb
- Bristol Myers Squibb Shares Drop Following Mixed Phase 3 Trial Results for Admilparant in IPF
- Bristol Myers Squibb Shares Rise on Positive Phase 3 Trial Results
- California Passes New Law to Regulate Robotaxis and Improve Emergency Response
- Bristol-Myers Squibb vs. Johnson & Johnson: Quarterly Revenue Comparison
- Fortune Announces Additional Speakers and Sponsors for Innovation Forum in Detroit
- Bristol Myers Squibb vs. Novo Nordisk: A Comparative Analysis of Healthcare Stocks for 2026
- Merck Receives FDA Approval to Update Label for Winrevair
- Bristol-Myers Squibb Outperforms Novartis Amid CAR-T Safety Concerns and Strong Financial Momentum
- Merck Shifts Focus from GARDASIL Decline to New Pipeline Opportunities
- Giovanni Caforio Appointed as Operating Advisor to CD&R Funds
- Atrium Therapeutics Reports Clinical Progress Amid Cash Burn Concerns
- Johnson & Johnson Collaborates with Sail Biomedicines for CAR-T Therapy Expansion
- Atrium Therapeutics Receives $15 Million Milestone Payment from Bristol-Myers Squibb
- Merck Stock Surpasses Peers Amid Strong Clinical Pipeline Results
- Bristol-Myers Squibb Ends Partnership with Cellares, Raising Concerns About Breyanzi Manufacturing
- BioNTech Rises Amid Post-Pandemic Biotech Surge but Faces Pressure to Improve Fundamentals
- Cellares Announces Layoffs Amid Restructuring Following Lost Partnership
- AstraZeneca's Potential Acquisition of Bristol-Myers Squibb Unlikely at This Time
- Stocks Making Significant Midday Moves: Amazon Hits $3 Trillion Market Cap as AI Infrastructure Gains Momentum
- AstraZeneca Shares Drop Amid Merger Rumors with Bristol Myers Squibb
- Dow Futures Rise Ahead of Busy Week for Wall Street
- AstraZeneca Leads Pharma Growth While Bristol Myers Trails Amid Merger Rumors
- Stocks Making Major Premarket Moves: Alibaba, AstraZeneca, eBay and More
- Morgan Stanley Maintains Underweight Rating on Bristol Myers Squibb Despite Strong Q2 Results
- U.S. Stock Futures Rise on Middle East De-escalation Hopes, Healthcare Sector Watched
- Ratio Therapeutics raises $70 million in Series C round to advance radiopharmaceutical pipeline
- Biggest Stock Movers on Monday Include BMY and BABA
- Alibaba Unveils Qwen3.8-Max AI Model, Surges in Hong Kong
- Morgan Stanley Maintains Underweight Rating on Bristol Myers Despite Strong Q2 Results
- AstraZeneca Shares Drop After Reported Merger Talks with Bristol Myers Squibb
- Markets React to Trump-Iran De-escalation, OPEC+ Output Hike
- AstraZeneca Considering $400 Billion Merger with Bristol Myers Squibb
- AstraZeneca Considering Merger with Bristol Myers Squibb, Report Says